Biotech | November 18, 2021
Daiichi Sankyo initiates Phase 2 trial of mRNA Covid-19 vaccine in Japan
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
The 50-bed hospital is positioned to address complexities specific to women and children, going beyond a birthing facility
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
The process is completed with the help of a balloon at a low temperature so that other cells are undamaged and the patient can return home the next day
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
Fortis Memorial Research Institute is the only hospital in India and South Asia to acquire the machine
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
Subscribe To Our Newsletter & Stay Updated
